Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.


Journal

Hematology (Amsterdam, Netherlands)
ISSN: 1607-8454
Titre abrégé: Hematology
Pays: England
ID NLM: 9708388

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 30 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: ppublish

Résumé

The clinical outcomes of multiple myeloma (MM) patients are highly variable in the real-world setting. Some MM patients may have clinical endings that do not abide by the book. We aim to describe features of MM patients with extreme survivals in real-world practice. This retrospective study enrolled 941 patients consecutively visited a national medical center, China, between July 1995 and December 2021. Among patients, we identified two groups of MM patients with extreme survivals, 56 were in the long-term remission (LR) group with progression-free survival (PFS) ≥ 60 months, and 82 were in the rapid progression (RP) group with PFS ≤ 6 months. CRAB features, of which hypercalcemia, renal insufficiency, and anemia were more common in the RP group, except for bone disease, with a comparable incidence at diagnosis in both groups (88.8 vs 85.7%, The disparities in the survivals of MM patients indicated that some unexpected factors have influenced the outcomes in the real-world setting.

Identifiants

pubmed: 38018564
doi: 10.1080/16078454.2023.2277503
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2277503

Auteurs

Liang Ren (L)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Yuhong Ren (Y)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Yang Yang (Y)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Wenjing Wang (W)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Tianhong Xu (T)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Yawen Wang (Y)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Jiadai Xu (J)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Aziguli Maihemaiti (A)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Tianwei Lan (T)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Panpan Li (P)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Chi Zhou (C)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Pu Wang (P)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Peng Liu (P)

Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH